Cassava Sciences (SAVA) Competitors $2.28 -0.10 (-4.20%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.27 -0.01 (-0.44%) As of 08/29/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SAVA vs. CRVS, KMDA, AURA, IMAB, YMAB, AQST, VIGL, OLMA, RCKT, and ZYBTShould you be buying Cassava Sciences stock or one of its competitors? The main competitors of Cassava Sciences include Corvus Pharmaceuticals (CRVS), Kamada (KMDA), Aura Biosciences (AURA), I-Mab (IMAB), Y-mAbs Therapeutics (YMAB), Aquestive Therapeutics (AQST), Vigil Neuroscience (VIGL), Olema Pharmaceuticals (OLMA), Rocket Pharmaceuticals (RCKT), and Zhengye Biotechnology (ZYBT). These companies are all part of the "pharmaceutical products" industry. Cassava Sciences vs. Its Competitors Corvus Pharmaceuticals Kamada Aura Biosciences I-Mab Y-mAbs Therapeutics Aquestive Therapeutics Vigil Neuroscience Olema Pharmaceuticals Rocket Pharmaceuticals Zhengye Biotechnology Cassava Sciences (NASDAQ:SAVA) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment. Which has more volatility and risk, SAVA or CRVS? Cassava Sciences has a beta of -2.06, meaning that its share price is 306% less volatile than the S&P 500. Comparatively, Corvus Pharmaceuticals has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Does the media prefer SAVA or CRVS? In the previous week, Cassava Sciences and Cassava Sciences both had 2 articles in the media. Corvus Pharmaceuticals' average media sentiment score of 1.62 beat Cassava Sciences' score of 1.20 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cassava Sciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corvus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts prefer SAVA or CRVS? Cassava Sciences currently has a consensus target price of $2.00, indicating a potential downside of 12.28%. Corvus Pharmaceuticals has a consensus target price of $15.00, indicating a potential upside of 161.32%. Given Corvus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than Cassava Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cassava Sciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Corvus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation and earnings, SAVA or CRVS? Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCassava SciencesN/AN/A-$24.34M-$2.55-0.89Corvus PharmaceuticalsN/AN/A-$62.29M-$1.01-5.68 Do institutionals & insiders believe in SAVA or CRVS? 38.0% of Cassava Sciences shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 2.4% of Cassava Sciences shares are owned by company insiders. Comparatively, 31.3% of Corvus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is SAVA or CRVS more profitable? Corvus Pharmaceuticals' return on equity of -28.61% beat Cassava Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Cassava SciencesN/A -66.16% -53.11% Corvus Pharmaceuticals N/A -28.61%-18.05% SummaryCorvus Pharmaceuticals beats Cassava Sciences on 10 of the 12 factors compared between the two stocks. Get Cassava Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SAVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SAVA vs. The Competition Export to ExcelMetricCassava SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$110.14M$2.49B$5.69B$9.74BDividend YieldN/A48.55%6.64%4.48%P/E Ratio-0.8922.8083.1926.59Price / SalesN/A544.56515.16159.07Price / CashN/A26.3325.6628.92Price / Book0.755.3711.766.08Net Income-$24.34M$32.95M$3.27B$265.93M7 Day Performance5.56%-0.65%1.13%0.36%1 Month Performance7.55%6.46%8.30%5.58%1 Year Performance-92.06%-3.15%62.26%19.67% Cassava Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SAVACassava Sciences2.0363 of 5 stars$2.28-4.2%$2.00-12.3%-92.1%$110.14MN/A-0.8930Positive NewsCRVSCorvus Pharmaceuticals3.1364 of 5 stars$5.45-1.8%$15.00+175.2%+28.1%$406.10MN/A-5.4030Positive NewsKMDAKamada4.7036 of 5 stars$7.05-1.8%$13.00+84.4%+20.3%$405.45M$160.95M20.74360Positive NewsAURAAura Biosciences1.7317 of 5 stars$6.52-0.5%$22.00+237.4%-21.3%$405.02MN/A-3.3350IMABI-Mab2.9383 of 5 stars$4.82-5.3%$6.50+34.9%+268.1%$393.60M$3.89M0.00380Positive NewsHigh Trading VolumeYMABY-mAbs Therapeutics2.4431 of 5 stars$8.52-0.1%$9.62+12.9%-40.3%$387.13M$85.39M-17.04150Positive NewsAQSTAquestive Therapeutics1.8071 of 5 stars$3.86-3.0%$10.14+162.8%-16.8%$384.94M$44.13M-5.51160Positive NewsVIGLVigil Neuroscience1.2808 of 5 stars$8.05flat$10.80+34.2%N/A$383.91MN/A-3.9340OLMAOlema Pharmaceuticals2.2385 of 5 stars$5.59-3.0%$24.00+329.3%-53.7%$383.64MN/A-2.8270News CoveragePositive NewsRCKTRocket Pharmaceuticals4.9559 of 5 stars$3.54-2.7%$16.73+372.7%-82.6%$381.98MN/A-1.41240ZYBTZhengye BiotechnologyN/A$8.00+14.6%N/AN/A$377.36M$25.53M0.00278Gap Down Related Companies and Tools Related Companies Corvus Pharmaceuticals Competitors Kamada Competitors Aura Biosciences Competitors I-Mab Competitors Y-mAbs Therapeutics Competitors Aquestive Therapeutics Competitors Vigil Neuroscience Competitors Olema Pharmaceuticals Competitors Rocket Pharmaceuticals Competitors Zhengye Biotechnology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SAVA) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersNew Banking Law #1582 Could Unlock $21 Trillion for AmericansDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cassava Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
